MichaelBoyiadzisMD
Oncology • Pittsburgh, PAAssistant Professor, Medicine, University of Pittsburgh School of Medicine
Are you Dr. Boyiadzis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 43 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 Meyran Ave
Suite 318
Pittsburgh, PA 15213Phone+1 412-586-9874Fax+1 412-647-4486- Is this information wrong?
Summary
- Dr. Michael Boyiadzis, MD is an oncologist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and Maryland. He is affiliated with UPMC Presbyterian Shadyside, UPMC Magee-Womens Hospital, and Shadyside Campus.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2001 - 2005
St Agnes HealthCareResidency, Internal Medicine, 1998 - 2001
University of Debrecen Medical and Health Science CenterClass of 1995
Certifications & Licensure
PA State Medical License 2004 - 2024
MD State Medical License 2001 - 2006
Clinical Trials
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
- QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2014 May 12
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
- Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.Normolle, D., Bovbjerg, D., Im, A., Quann, K., Agha, M., Raptis, A., Redner, R., Hou, J., Farah, R., Dorritie, K., Sehgal, A., Aggarwal, N., Herman, J., Lontos, K., Bo...> ;American Journal of Hematology. 2024 Mar 1
- Blast-Derived Small Extracellular Vesicles in the Plasma of Patients with Acute Myeloid Leukemia Predict Responses to Chemotherapy.Hong, C., Yerneni, S., Im, A., Diergaarde, B., Whiteside, T., Boyiadzis, M.> ;Biomedicines. 2023 Dec 7
- Join now to see all
Press Mentions
- DPP4+ Exosomes in AML Patients’ Plasma Suppress Proliferation of Hematopoietic Progenitor CellsNovember 2nd, 2020
Hospital Affiliations
UPMC Presbyterian ShadysidePittsburgh, Pennsylvania- Shadyside CampusPittsburgh, Pennsylvania
UPMC Magee-Womens HospitalPittsburgh, Pennsylvania
